Surgical Treatment of Childhood Inflammatory Myofibroblastic Tumors

Abstract

Aim A retrospective study was performed to evaluate the clinical features, diagnostic methods, and treatment alternatives of childhood inflammatory myofibroblastic tumors (IMTs).

Patients and Methods Patients who underwent surgical treatment for IMT between 2000 and 2015 were evaluated for age, sex, presenting symptoms, physical examination findings, diagnostic methods, treatment modalities, histopathologic findings, and results of surgical treatment during long-term follow-up.

Results Eleven patients who underwent surgical treatment were included in the study. Male:female ratio was 7:4 and the mean age of the patients was 6.09 years (1–10 years). Presenting symptoms were respiratory difficulty, cough (n = 7, 63.3%), abdominal pain, vomiting (n = 2, 18.8%), loss of body weight (n = 1, 9.09%), palpable mass (n = 1, 9.09%), and rectal bleeding (n = 1, 9.09%). Ultrasonography (n = 4, 36.3%) and computed tomography (n = 9, 81.1%) were used for diagnosis. Localizations of tumors were lungs (n = 5, 45.4%), mediastinum (n = 2, 18.1%), spleen (n = 1, 9.09%), neck (n = 1, 9.09%), colon (n = 1, 9.09%), and rectum (n = 1, 9.09%). The mean size of mass was 6.6 cm (2–12 cm) and six patients were diagnosed with preoperative biopsy. Lung lobectomy (right lower lobe; n = 3, right middle and lower lobe; n = 2), total resection of mass with adjacent bowel (n = 2), partial splenectomy (n = 1), total resection of neck mass (n = 1), and incomplete resection (n = 2) were the choice of surgical treatment. Incomplete resection was performed in masses closely adjacent to atrium and mediastinal structures. In histopathologic evaluation, surgical margins were free of tumor in four cases, positive in six cases, and were not reported in one case. Anaplastic lymphoma kinase (ALK) positivity was detected in six cases, negative in two cases, and was not evaluated in three cases. Two cases who had residual mass with positive ALK received chemotherapy. Mean follow-up time was 68.2 months (5 months to 12 years). During follow-up, there was no recurrence or distant metastasis. Ten patients survived and one patient was lost to follow-up.

Conclusion IMT is a rare tumor of childhood with a spectrum of clinical findings because of variable localization. Surgical treatment is the first choice of treatment. Patients with residual mass and ALK positivity may require medical treatment. In our series, long-term survival of patients was favorable in patients with total resection.

Keywords

inflammatory myofibroblastic tumor - children - ALK

• References

• 1 Karnak I, Şenocak ME, Çiftçi AÖ. , et al. Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg 2001; 36 (06) 908-912
• 2 Çiftçi AÖ, Akçören Z, Tanyel FC, Şenocak ME, Cağlar M, Hiçsönmez A. Inflammatory pseudotumor causing intestinal obstruction: diagnostic and therapeutic aspects. J Pediatr Surg 1998; 33 (12) 1843-1845
• 3 Buccoliero AM, Ghionzoli M, Castiglione F. , et al. Inflammatory myofibroblastic tumor: clinical, morphological, immunohistochemical and molecular features of a pediatric case. Pathol Res Pract 2014; 210 (12) 1152-1155
• 4 Oğuz B, Ozcan HN, Omay B, Ozgen B, Haliloglu M. Imaging of childhood inflammatory myofibroblastic tumor. Pediatr Radiol 2015; 45 (11) 1672-1681
• 5 Brunn H. Two interesting benign tumors of contradictory histopathology: remarks on the necessity for maintaining the chest tumor registry. J Thorac Cardiovasc Surg 1939; 9: 119-131
• 6 Panagiotopoulos N, Patrini D, Gvinianidze L, Woo WL, Borg E, Lawrence D. Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm?. J Thorac Dis 2015; 7 (05) 908-911
• 7 Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumor. In: Fletcher CDM, Unni KK, Mertens F. eds. Pathology and Genetics of Tumors of Soft Tissue and Bone. Vol 5. Lion, France: IARC Press; 2002: 91-93
• 8 Karnak I, Haliloğlu M, Orhan D, Yalçin B, Kalaycı Ö. Pure endobronchial inflammatory myofibroblastic tumor in children. J Pediatr Hematol Oncol 2014; 36 (02) 108-110
• 9 Dalton BG, Thomas PG, Sharp NE. , et al. Inflammatory myofibroblastic tumors in children. J Pediatr Surg 2016; 51 (04) 541-544
• 10 Mehta B, Mascarenhas L, Zhou S, Wang L, Venkatramani R. Inflammatory myofibroblastic tumors in childhood. Pediatr Hematol Oncol 2013; 30 (07) 640-645
• 11 Maples MD, Adkins Jr RB, Graham BS, Dao AH, Scott Jr HW. Pseudotumor of the lung. Am Surg 1985; 51 (02) 84-88
• 12 Johnson K, Notrica DM, Carpentieri D, Jaroszewski D, Henry MM. Successful treatment of recurrent pediatric inflammatory myofibroblastic tumor in a single patient with a novel chemotherapeutic regimen containing celecoxib. J Pediatr Hematol Oncol 2013; 35 (05) 414-416
• 13 Butrynski JE, D'Adamo DR, Hornick JL. , et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363 (18) 1727-1733
• 14 Zhao JJ, Ling JQ, Fang Y. , et al. Intra-abdominal inflammatory myofibroblastic tumor: spontaneous regression. World J Gastroenterol 2014; 20 (37) 13625-13631
• 15 Meis JM, Enzinger FM. Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor. Am J Surg Pathol 1991; 15 (12) 1146-1156
• 16 Kubo N, Harada T, Anai S. , et al. Carboplatin plus paclitaxel in the successful treatment of advanced inflammatory myofibroblastic tumor. Intern Med 2012; 51 (17) 2399-2401
• 17 Janik JS, Janik JP, Lovell MA, Hendrickson RJ, Bensard DD, Greffe BS. Recurrent inflammatory pseudotumors in children. J Pediatr Surg 2003; 38 (10) 1491-1495
• 18 Kırlı EA, Orhan D, Haliloğlu M, Karnak I. Invasive inflammatory myofibroblastic tumor of the spleen treated with partial splenectomy in a child. J Pediatr Hematol Oncol 2012; 34 (04) 131-133